Evgen Pharma PLC Result of AGM and Business Update (1300F)
13 Julio 2021 - 11:02AM
UK Regulatory
TIDMEVG
RNS Number : 1300F
Evgen Pharma PLC
13 July 2021
Evgen Pharma plc
("Evgen" or the "Company")
Result of AGM and Business Update
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, is pleased to provide a business update
following today's Annual General Meeting, at which all resolutions
were duly passed.
The AGM voting results will be available on the Company's
website later today:
https://evgen.com/investors/shareholder-information/
During the last few months we have made significant progress in
our glioblastoma ('GBM') development programme, building on
exciting initial data from the University L'Aquila which
demonstrated tumour shrinkage and significantly extended survival
times in in vivo models of GBM. Further work at The University of
Auckland and with a Clinical Research Organisation has
substantiated and expanded upon important elements of these data,
and we are well-advanced in generating a pre-clinical data package
that would justify moving into a Phase II clinical trial. We
currently project such a trial commencing in the first half of
2022. In parallel with this activity, we have applied for Orphan
Drug status for SFX-01 in GBM from the US Food and Drug
Administration (FDA) and we are compiling an Investigational New
Drug application to be submitted to the FDA later this year.
As announced earlier today, we are pleased to report preliminary
in vitro data showing the significant reduction of cell
proliferation and increased apoptosis (cell death) of Juvenile
Myelomonocytic Leukaemia stem cells in the presence of SFX-01,
compared to normal controls. The study also showed that SFX-01
significantly impacted cell proliferation and increased
cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell
line. The data were generated by Dr Eleni Louka and Professor Adam
Mead of the MRC Weatherall Institute of Molecular Medicine at
Oxford University. We are investigating options for building on
this data with potential scientific partners.
Whilst we were disappointed with the outcome of the STAR trial
(SFX-01 in Acute Respiratory Distress Syndrome patients) we would
emphasise that this was an opportunistic trial funded almost
entirely by third parties. Analysis of the unblinded data from the
trial will generate substantial bioanalytical insight from the
treated patients, which will be valuable to our further development
programmes.
Last month we were pleased to report that our collaborators at
the Manchester Breast Centre, the University of Manchester, are
conducting further in vitro preclinical work to assess the impact
of SFX--01 in CDK4/6 resistance models. An increasing body of data
from there shows that in these models SFX--01 may suppress tumour
growth and metastasis in patients who have become resistant to
CDK4/6 inhibitors (palbociclib, Ibrance, Pfizer). In particular,
SFX--01 reduced the viability and mammosphere colony formation
ability of palbociclib--resistant cells in vitro.
In summary, the Company is well funded to execute pre-clinical
and/or clinical programmes in oncology and looks forward to
updating the market on these programmes in due course.
An updated presentation on the Company is available on at:
https://evgen.com/investors/shareholder-information/ under 'Latest
AGM Presentation'.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7876 741 001 / +44 (0)7980 541
Anna Dunphy / Paul McManus 893
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The has its headquarters at Alderley Park, Cheshire , and its
registered office is at the Liverpool Science Park, Liverpool. It
is listed on the AIM market of the London Stock Exchange and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGEAKXDFEEFEFA
(END) Dow Jones Newswires
July 13, 2021 12:02 ET (16:02 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024